ShareValue scores for LITS: Valuation 54, Quality 44, Growth 56, Health 51.
LITSNASDAQ
Lite Strategy, Inc.
$0.93
(-2.76%)
LITSNASDAQ
Lite Strategy, Inc.
$0.93(-2.76%)
Loading chart...
Sentiment
Verdicts
Value:Fair Value
Quality:Moderate
Growth:Moderate
Health:Moderate
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
6% to 17%
Rating
Trap Risk
Return
6% to 17%
Valuation
54
Fair Value
Price vs Value
Quality
44
Moderate
Business Strength
Growth
56
Moderate
Revenue & Earnings
Health
51
Moderate
Financial Stability
Momentum
59
Neutral
Price Trend
Company Details
About
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Market Cap$32M
P/E RatioN/A
Dividend YieldNone
Sector Rank#1078
Score Analysis
AI Investment Thesis
Data as of:Aug 7, 2026
|Last calculated:Aug 7, 2026